Where is Kantify located?

Kantify is headquartered in Brussels, Belgium.

Who is the current CEO of Kantify?

Segolene Martin of Kantify. They have also founded 1 company.

How many employees does Kantify have?

As of Mar 31, 2026, the latest employee count at Kantify is 13.

Is Kantify a funded company?

Kantify is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Kantify rank among its competitors?

Kantify ranks 3618th amongst 3803 active competitors, of which 1304 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Kantify?

Kantify's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Kantify - 2026 Company Profile, Team, Competitors & Financials

Kantify is a funded company based in Brussels (Belgium), founded in 2016 by Nik Subramanian and Segolene Martin. It operates as a Developer of AI-based software solutions. The company has 3803 active competitors, including 1304 funded and 868 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.

Company Details

Developer of AI-based software solutions. It develops software that assists with drug diagnosis and analysis. It comes with features for in-silico drug targeting, target identification, predictive diagnosis, laboratory automation, and more.

Website: kantify.com
Social
Email ID: *****@kantify.com
Phone Number: +32 **********

Key Metrics

Founded Year

2016

Location

Brussels, Belgium

Stage

Funding Raised

Ranked

3618^th among 3803 active competitors

Employee Count

13 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 5949 more

View Kantify's full profile

Kantify is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kantify CIN: 0628.692.731 , Belgium, Active	May 31, 2015	-	1 (As on Apr 30, 2022)	-

Kantify is a funded company. Kantify has 1 institutional investor.

The founders of Kantify are Nik Subramanian and Segolene Martin. Segolene Martin is the CEO of Kantify.

Here are the details of Kantify's key team members:

Nik Subramanian: Co-Founder of Kantify.
Segolene Martin: Co-Founder & CEO of Kantify.
Contact Info: 1 email address and 1 phone number

View details of Kantify's Founder profiles and Board Members

Kantify's employee count trend

Kantify has 13 employees as of Mar 26. Here is Kantify's employee count trend over the years:

Uncover Kantify's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kantify include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Kantify, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
3618th	Kantify 2016, Brussels (Belgium), Funding Raised	Developer of AI-based software solutions	-	-	28/100